Teva, P&G to build Indian plant for $89m

Joint venture PGT Healthcare will produce consumer health and over-the-counter products at the Gujarat factory.

PGT Healthcare, the joint venture of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Procter & Gamble Co. (NYSE: PG), will set up a plant in India to produce consumer health and over-the-counter products, at an investment of 5 billion rupees ($89 million). The plant will produce for both the Indian domestic market and for export.

The plant in Sanand, Gujarat, will produce inhalers, throat drops and cough syrups under P&G's Vicks brand. PGT Healthcare's initial investment will be 2.5 billion rupees.

State of Gujarat’s Commissioner for Food and Drug Control Administration H G Kohsia said, “A four-member delegation led by Teva VP corporate quality Karin Baer met us and sought details of setting up a facility to manufacture OTC products like cough syrups, inhalers, among others." The delegation's other members were Teva Assistant VP Rajiv Palliwal, Senior Director OTC Operations Haresh Gill, and Seema Sundereshan, a senior scientist from P&G.

Kohsia added that the proposed facility would have state-of-the-art equipment and adhere to good manufacturing practices norms to make products both for Indian and overseas market. It will initially hire 500 people, which could rise to 1,000.

India's "Business Standard" quotes Gujarat officials as saying that a formal announcement is likely to be made after the signing of a memorandum of understanding with the state government during the Vibrant Gujarat Global Summit-2013 scheduled for January next year.

Published by Globes [online], Israel business news - - on July 26, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017